Ketazocine
 | |
| Systematic (IUPAC) name | |
|---|---|
| (2S,6R,11R)-3-(cyclopropylmethyl)-8-hydroxy-6,11-dimethyl-3,4,5,6-tetrahydro-2,6-methano-3-benzazocin-1(2H)-one | |
| Clinical data | |
| |
| Oral | |
| Identifiers | |
36292-69-0  | |
| None | |
| PubChem | CID 3054741 |
| ChemSpider |
2316328 |
| UNII |
6IO4IG518S |
| KEGG |
D04649 |
| Chemical data | |
| Formula | C18H23NO2 |
| 285.38 g/mol | |
|
SMILES
| |
| |
| (what is this?) (verify) | |
Ketazocine (INN), also known as ketocyclazocine, is a benzomorphan derivative used in opioid receptor research. Ketocyclazocine is an exogenous opioid that binds to the kappa opioid receptor.[1]
Activation of this receptor is known to cause sleepiness, a decrease in pain sensation and (potentially) dysphoria, paranoia, and hallucinations. It also causes an increase in urine production because it inhibits the release of vasopressin. (Vasopressin is an endogenous substance that assists in regulating fluid and electrolyte balance in the body and decreases the amount of water released into the urine.)
Unlike other opioids, substances that only bind to the kappa receptor theoretically do not depress the respiratory system.
See also
References
- ↑ Leander JD (Sep 1982). "Effects of ketazocine, ethylketazocine and phenazocine on schedule-controlled behavior: antagonism by naloxone". Neuropharmacology 21 (9): 923–8. doi:10.1016/0028-3908(82)90085-5. PMID 6128693.
| ||||||||||||||||||||||||||||||||||||||